Pi Pharma Intelligence’s Post

Which molecules are reaching phase 3 trials? Understanding which molecule types are reaching phase 3 trials can guide pharmaceutical companies' decision-making, enabling them to explore candidates that are more likely to make it to a phase 3 trial. At the same time, this understanding can also give organisations insight into new areas of opportunity, by revealing underexplored molecule types. In an increasingly competitive industry, this can help give your company an edge. Take a look at our analysis below and get in touch to learn more! #PharmaceuticalInsights #MoleculeTypes #Phase3Trials #Pharmaceuticals

Register below to learn more about the emerging important role of methylation-based ctDNA testing applications in MRD and response monitoring!

Check out the webcast next Wednesday (7/17) to learn about Adverum’s advances in the treatment of nAMD!

🔬 Unraveling the Placebo-Adherence Enigma in Clinical Trials 🔬 Exciting new insights emerge from our latest blog post "Placebo And Adherence: Is A Complicated Relationship Compromising Clinical Trial Effectiveness?" Highlighting a century of mystery since T.C. Graves first defined the placebo effect, we delve into the nuanced relationship between adherence and placebo responses in clinical trials. Our article explores pivotal findings, starting with the landmark Coronary Drug Project Research Group study in 1980, which first linked adherence rates to mortality differences, even among placebo groups. This intriguing correlation challenges conventional trial methodologies and prompts a deeper look into how we measure and interpret adherence in clinical settings. With cutting-edge analyses and recent advancements in digital monitoring, we're poised to refine our understanding of the 'healthy adherer' effect and enhance trial integrity. Join us as we discuss how these insights could revolutionize clinical trial outcomes and potentially recalibrate regulatory approaches. 📈 Dive into our comprehensive analysis here: https://hubs.li/Q02vt-JV0 #ClinicalTrials #PlaceboEffect #HealthcareInnovation #Adherence #MedicalResearch

Are you struggling with duplicate and professional research subjects? Look no further than Verified Clinical Trials ™ (VCT)! VCT is a cross-sponsor database covering phase I-IV across multiple therapeutic indications globally. With VCT, you can save time and money while ensuring your clinical trial meets its endpoints. Contact VCT at connect@verifiedclinicaltrials.com to learn more! #duplicatesubjects #verifiedclinicaltrials #placeboresponse

Have you participated in a clinical trial? Now is the time! Together, the FRAXA Research Foundation and the National Fragile X Foundation encourage families living with Fragile X to participate in clinical trials. We do not currently have an approved treatment for Fragile X syndrome, though there are a few under investigation. Investigational treatments go through rigorous testing, including clinical trials, and must be approved by the FDA before they are available for public use. There are several investigational treatments being researched to treat Fragile X and there are currently two active late stage clinical trials. Clinical trials are the reason we will eventually have effective treatments and ultimately a cure for Fragile X syndrome. Consider participating in a clinical trial today! #FragileX #FXResearch #ClinicalTrials #ResearchAdvances #FragileXCommunity #GeneticResearch #HopeForFragileX #MedicalResearch #SupportResearch #FindACure

First-of-its-kind Human Trial to be revealed at ASCO 2024. First-in-human trials act as the bridge for advancing new, promising drug candidates and are primarily conducted to establish the safe dosage range for subsequent clinical development. Numerous stakeholders are actively engaged in discussing their first-in-human trial data findings. This data appears highly compelling, particularly in the context of the innovative class of therapies currently in development within the pipeline. For more captivating insights, visit: https://lnkd.in/dj6Za_QE #FirstInHuman #ClinicalTrials #DrugDevelopment #SafeDose #MedicalResearch #TherapeuticInnovation #PipelineProgress #ClinicalData #HealthcareAdvancement

If you are developing a medicine for a rare disease and have more questions about Orphan Drug Designation, watch our webinar “Orphan Drug Designation - Do You Have the Global Strategy?” now on YouTube! Access the online recording of the webinar using the link below: https://lnkd.in/dWyuaS2e The webinar will help you understand the benefits of Orphan Drug Designation, providing insights on how to use OD as a tool for significant financial discounts or additional scientific support. You will also gain a deeper understanding of the advantages of applying simultaneously to ODs globally and the specific  benefits provided by each region. For any further questions, please contact our expert,  Liam Spencer. #LumisInternational #OrphanDrugDesignation #OrphanMedicine #OrphanDesignation

If you are developing a medicine for a rare disease and have more questions about Orphan Drug Designation, watch our webinar “Orphan Drug Designation - Do You Have the Global Strategy?” now on YouTube! Access the online recording of the webinar using the link below: https://lnkd.in/dWyuaS2e The webinar will help you understand the benefits of Orphan Drug Designation, providing insights on how to use OD as a tool for significant financial discounts or additional scientific support. You will also gain a deeper understanding of the advantages of applying simultaneously to ODs globally and the specific  benefits provided by each region. For any further questions, please contact our expert,  Liam Spencer. #LumisInternational #OrphanDrugDesignation #OrphanMedicine #OrphanDesignation

What is the most appropriate primary endpoint in RA clinical trials? ACR20/50/70? We pooled data from pivotal RA drug trials, and investigated ACR response dynamics in different patient polulations- to find the optimal balance between discriminative capacity and clinical relevance, at different timepoints over the course of a study. https://lnkd.in/dr_e_vpH